Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse

Manuel Salavisa; Pedro Paixão; Ana Filipa Ladeira; Alexandra Mendes; Ana Sofia Correia; João Faro Viana; Miguel Viana-Baptista

doi:10.1016/j.jneuroim.2020.577355

Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse

Manuel Salavisa, Pedro Paixão, Ana Filipa Ladeira, Alexandra Mendes, Ana Sofia Correia, João Faro Viana, Miguel Viana-Baptista

NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Given its highly variable clinical course, an unmet need for objective prognostic assessment in Multiple Sclerosis (MS) persists. In this work, we suggest that CSF kappa free light chains (KFLC) determination at first relapse may provide insight into future disease activity and disability worsening. We quantified KFLC by nephelometry in paired CSF/serum samples of 28 patients, collected within one month of first-ever MS relapse, and explored correlations with clinical data on disease activity, retrospectively registered across a median follow-up time of 79 months. We documented KFLC ratio (CSF-FKLC/Serum-KFLC) as an independent predictor of second relapse occurrence and disability worsening at follow-up, in this cohort.

Original language	English
Article number	577355
Journal	Journal of Neuroimmunology
Volume	347
DOIs	https://doi.org/10.1016/j.jneuroim.2020.577355
Publication status	Published - 15 Oct 2020

Keywords

Disease activity
Kappafree light chains
MS biomarkers
Multiple sclerosis

Access to Document

10.1016/j.jneuroim.2020.577355

Cite this

@article{a5c5e28f394149e78a3d1cf828d95607,

title = "Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse",

abstract = "Given its highly variable clinical course, an unmet need for objective prognostic assessment in Multiple Sclerosis (MS) persists. In this work, we suggest that CSF kappa free light chains (KFLC) determination at first relapse may provide insight into future disease activity and disability worsening. We quantified KFLC by nephelometry in paired CSF/serum samples of 28 patients, collected within one month of first-ever MS relapse, and explored correlations with clinical data on disease activity, retrospectively registered across a median follow-up time of 79 months. We documented KFLC ratio (CSF-FKLC/Serum-KFLC) as an independent predictor of second relapse occurrence and disability worsening at follow-up, in this cohort.",

keywords = "Disease activity, Kappafree light chains, MS biomarkers, Multiple sclerosis",

author = "Manuel Salavisa and Pedro Paix{\~a}o and Ladeira, {Ana Filipa} and Alexandra Mendes and Correia, {Ana Sofia} and Viana, {Jo{\~a}o Faro} and Miguel Viana-Baptista",

year = "2020",

month = oct,

day = "15",

doi = "10.1016/j.jneuroim.2020.577355",

language = "English",

volume = "347",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

TY - JOUR

T1 - Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse

AU - Salavisa, Manuel

AU - Paixão, Pedro

AU - Ladeira, Ana Filipa

AU - Mendes, Alexandra

AU - Correia, Ana Sofia

AU - Viana, João Faro

AU - Viana-Baptista, Miguel

PY - 2020/10/15

Y1 - 2020/10/15

N2 - Given its highly variable clinical course, an unmet need for objective prognostic assessment in Multiple Sclerosis (MS) persists. In this work, we suggest that CSF kappa free light chains (KFLC) determination at first relapse may provide insight into future disease activity and disability worsening. We quantified KFLC by nephelometry in paired CSF/serum samples of 28 patients, collected within one month of first-ever MS relapse, and explored correlations with clinical data on disease activity, retrospectively registered across a median follow-up time of 79 months. We documented KFLC ratio (CSF-FKLC/Serum-KFLC) as an independent predictor of second relapse occurrence and disability worsening at follow-up, in this cohort.

AB - Given its highly variable clinical course, an unmet need for objective prognostic assessment in Multiple Sclerosis (MS) persists. In this work, we suggest that CSF kappa free light chains (KFLC) determination at first relapse may provide insight into future disease activity and disability worsening. We quantified KFLC by nephelometry in paired CSF/serum samples of 28 patients, collected within one month of first-ever MS relapse, and explored correlations with clinical data on disease activity, retrospectively registered across a median follow-up time of 79 months. We documented KFLC ratio (CSF-FKLC/Serum-KFLC) as an independent predictor of second relapse occurrence and disability worsening at follow-up, in this cohort.

KW - Disease activity

KW - Kappafree light chains

KW - MS biomarkers

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85089227740&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2020.577355

DO - 10.1016/j.jneuroim.2020.577355

M3 - Article

C2 - 32795735

AN - SCOPUS:85089227740

VL - 347

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

M1 - 577355

ER -

Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this